MCID: RNL034
MIFTS: 22

Renal Cell Carcinoma 4

Categories: Rare diseases, Nephrological diseases, Cancer diseases, Genetic diseases

Aliases & Classifications for Renal Cell Carcinoma 4

MalaCards integrated aliases for Renal Cell Carcinoma 4:

Name: Renal Cell Carcinoma 4 50
Rcc4 50

Classifications:



Summaries for Renal Cell Carcinoma 4

MalaCards based summary : Renal Cell Carcinoma 4, also known as rcc4, is related to renal cell carcinoma and endotheliitis. An important gene associated with Renal Cell Carcinoma 4 is DIRC2 (Disrupted In Renal Carcinoma 2). The drugs Bevacizumab and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include kidney, lung and t cells.

Related Diseases for Renal Cell Carcinoma 4

Diseases in the Renal Cell Carcinoma family:

Hereditary Renal Cell Carcinoma Renal Clear Cell Carcinoma
Renal Cell Carcinoma 4

Diseases related to Renal Cell Carcinoma 4 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 renal cell carcinoma 10.1
2 endotheliitis 9.6

Symptoms & Phenotypes for Renal Cell Carcinoma 4

Drugs & Therapeutics for Renal Cell Carcinoma 4

Drugs for Renal Cell Carcinoma 4 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 310)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
2
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
4
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
5
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 341031-54-7, 557795-19-4 5329102
6
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 284461-73-0 216239 406563
7
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
8
Zoledronic acid Approved Phase 4,Phase 2 118072-93-8 68740
9
Aldesleukin Approved Phase 4,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
10
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
11
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 1 51-43-4 5816
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
13 Racepinephrine Approved Phase 4,Phase 2,Phase 1
14
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
15
Nicotine Approved Phase 4 54-11-5 942 89594
16
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
17
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
18
nivolumab Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 946414-94-4
19
Gemcitabine Approved Phase 4,Phase 2 95058-81-4 60750
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 59-30-3 6037
21
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 59-67-6 938
22
Nicotinamide Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 98-92-0 936
23
Caffeine Approved, Nutraceutical Phase 4 58-08-2 2519
24 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
25 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
26 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
28 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
30 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
31 interferons Phase 4,Phase 2,Phase 3,Phase 1
32 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Interleukin-2 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Micronutrients Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
35 Nicotinic Acids Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
36 Trace Elements Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
37 Vitamin B Complex Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
38 Vitamins Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
39 Interferon-alpha Phase 4,Phase 2,Phase 3,Phase 1
40 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
41 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
42 Adjuvants, Anesthesia Phase 4,Phase 1
43 Anesthetics Phase 4,Phase 2,Phase 1
44 Anesthetics, General Phase 4,Phase 1
45 Anesthetics, Intravenous Phase 4,Phase 1
46 Anti-Anxiety Agents Phase 4,Phase 1
47 Central Nervous System Depressants Phase 4,Phase 2,Phase 1
48 Central Nervous System Stimulants Phase 4
49
Erlotinib Hydrochloride Phase 4,Phase 2,Phase 1 183319-69-9 176871
50 GABA Agents Phase 4,Phase 1

Interventional clinical trials:

(show top 50) (show all 482)

id Name Status NCT ID Phase Drugs
1 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
2 Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4 Everolimus
3 Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma Completed NCT00706706 Phase 4 Sunitinib Malate (SU011248)
4 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
5 Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2. Completed NCT01339962 Phase 4
6 SUTENT® In The First Line Treatment Of Renal Cell Carcinoma Completed NCT00460798 Phase 4
7 Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4 Everolimus (RAD001)
8 First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma Completed NCT01521715 Phase 4 Pazopanib
9 Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Completed NCT00172003 Phase 4 Zoledronic acid
10 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
11 Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
12 Sorafenib in Elderly mRCC Completed NCT01728948 Phase 4 Sorafenib (Nexavar, BAY43-9006)
13 Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours Completed NCT02016391 Phase 4 Dexmedetomidine
14 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
15 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
16 Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy Recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
17 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
18 Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma Recruiting NCT02399124 Phase 4
19 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Recruiting NCT02555748 Phase 4 Pazopanib;Sunitinib
20 A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma. Recruiting NCT01206764 Phase 4 RAD001
21 Use of Human Dehydrated Amnion/Chorion (DHACM) Allograft in Partial Nephrectomy Recruiting NCT03323021 Phase 4
22 An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Active, not recruiting NCT02596035 Phase 4 Nivolumab
23 Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) Active, not recruiting NCT01266837 Phase 4 Everolimus
24 Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
25 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) Terminated NCT02338570 Phase 4 Everolimus
26 Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients Terminated NCT01073644 Phase 4 Sunitinib malate
27 Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy Terminated NCT01486550 Phase 4 Voluven (Hydroxyethyl starch 130/0,4);Sodium Chloride 9mg/ml
28 Cost Effectiveness Of Sunitinib In Central America And Caribbean Terminated NCT01033981 Phase 4 Sunitinib
29 Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib Terminated NCT00352859 Phase 4 Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only)
30 A Post Marketing Surveillance As Required By Philippine Food And Drug Administration Withdrawn NCT01781442 Phase 4 Temsirolimus
31 Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer Withdrawn NCT01353794 Phase 4 Sorafenib (Nexavar, BAY43-9006)
32 Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Unknown status NCT01481870 Phase 3 Sorafenib-sunitinib;Sunitinib-sorafenib
33 Caphosol in Oral Mucositis Due to Targeted Therapy Completed NCT01265810 Phase 3
34 Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma Completed NCT02883153 Phase 2, Phase 3 Zirconium-89 girentuximab PET/CT
35 A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma Completed NCT01030783 Phase 3 tivozanib (AV-951);Sorafenib
36 ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma Completed NCT00420888 Phase 2, Phase 3 ABR-217620/naptumomab estafenatox;IFN-alpha
37 Sequential Study to Treat Renal Cell Carcinoma Completed NCT00732914 Phase 3 Sunitinib (Sutent);Sorafenib (Nexavar)
38 Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II) Completed NCT01613846 Phase 3 Sorafenib+Pazopanib;Pazopanib+Sorafenib
39 Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody Completed NCT00606632 Phase 3 124-Iodine-cG250 (124I-cG250)
40 IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma Completed NCT01265901 Phase 3 Sunitinib;Cyclophosphamide;IMA901
41 Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) Completed NCT00072046 Phase 3
42 SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma Completed NCT00083889 Phase 3 Interferon-alfa;SU011248
43 Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Completed NCT00326898 Phase 3 Sorafenib;Sunitinib
44 Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma Completed NCT01223027 Phase 3 Dovitinib;Sorafenib
45 Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer Completed NCT00002611 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
46 Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma Completed NCT00334282 Phase 3 Pazopanib;placebo
47 Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors Completed NCT00002610 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
48 A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) Recruiting NCT02684006 Phase 3 Avelumab (MSB0010718C);Axitinib (AG-013736);Sunitinib
49 Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery Recruiting NCT02535351 Phase 3 sunitinib or pazopanib
50 A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma Recruiting NCT03138512 Phase 3 Placebo

Search NIH Clinical Center for Renal Cell Carcinoma 4

Genetic Tests for Renal Cell Carcinoma 4

Anatomical Context for Renal Cell Carcinoma 4

MalaCards organs/tissues related to Renal Cell Carcinoma 4:

39
Kidney, Lung, T Cells, Prostate, Liver, Bone, Endothelial

Publications for Renal Cell Carcinoma 4

Articles related to Renal Cell Carcinoma 4:

id Title Authors Year
1
Retroperitoneal recurrence of a stage 1 renal cell carcinoma 4 years following core biopsy and fine needle aspiration: possible needle tract seeding. ( 22833375 )
2013
2
Retroperitoneal recurrence of a stage 1 renal cell carcinoma 4 years following core biopsy and fine needle aspiration: possible needle tract seeding. ( 22833531 )
2013
3
The value of nephron-sparing surgery for the treatment of renal cell carcinoma 4 to 7 cm in size. ( 23221132 )
2012
4
Optimal margin in nephron-sparing surgery for renal cell carcinoma 4 cm or less. ( 14499679 )
2003
5
[Optimal margin in nephron-sparing surgery for renal cell carcinoma 4 cm or less in diameter]. ( 12783662 )
2003
6
Nephron sparing surgery for renal cell carcinoma 4 cm. or less in diameter: indicated or under treated? ( 9554334 )
1998

Variations for Renal Cell Carcinoma 4

Expression for Renal Cell Carcinoma 4

Search GEO for disease gene expression data for Renal Cell Carcinoma 4.

Pathways for Renal Cell Carcinoma 4

GO Terms for Renal Cell Carcinoma 4

Sources for Renal Cell Carcinoma 4

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....